Melbourne, Australia 27 March 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25 – 30, 2025 in Chicago, IL.
New preclinical data on lead asset IVX037 and second asset IVX055, both bioselected oncolytic RNA immunotherapies, will be presented in a poster outlining their potent anti-tumour activity across a range of tumour types.
The second poster will include an overview of the completed phase 1a monotherapy clinical study of IVX037 and the design and progress of the Phase 1b clinical trial of IVX037 in combination with TYVYT® (sintilimab, a PD1 inhibitor). Both studies are in patients with advanced MSS-colorectal, gastroesophageal or ovarian cancer.
Details of the data presentations are as follows:
Presentation Title | Novel oncolytic RNA viruses, IVX037 and IVX055, demonstrate potent antitumor activity | Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer |
Presentation Date and Time | Sunday, April 27, 2025, 2-5PM CST | Monday, April 28, 2025, 2-5PM CST |
Abstract Number | 2635 | 9629 |
Location | Poster Section 35 | Poster Section 51 |
Session Title | Vaccines and Cell Therapies | Phase I Clinical Trials in Progress 1 |
About ImmVirX:
ImmVirX is developing novel oncolytic immunotherapies to create powerful new cancer therapy combinations. Our lead asset, IVX037, is in clinical studies with our second agent, IVX055, in pre-clinical development. Our novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce local and systemic anti-tumour immune responses.
The proprietary bio-selection platform enables the development of RNA viruses targeting specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.
In this way, our oncolytic immunotherapies are intended to increase the effectiveness of current therapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, ovarian, lung and liver cancer.
Website: https://www.immvirx.com/
Twitter: https://twitter.com/ImmVirX
LinkedIn: https://www.linkedin.com/company/immvirx
Media Contact
Dr. Malcolm McColl
Chief Executive Officer, Acting Chairman and Co-Founder
E: [email protected]
